Synthaverse S.A. (SVE.WA)
PLN 4.28
(7.0%)
PLN 4.28
(7.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 58.6 Million PLN | 16.32% |
| 2022 | 50.38 Million PLN | 22.43% |
| 2021 | 41.15 Million PLN | 2.48% |
| 2020 | 40.15 Million PLN | 2.69% |
| 2019 | 39.1 Million PLN | 21.1% |
| 2018 | 32.29 Million PLN | 2.83% |
| 2017 | 31.4 Million PLN | -13.58% |
| 2016 | 36.33 Million PLN | -14.67% |
| 2015 | 42.58 Million PLN | 26.84% |
| 2014 | 33.57 Million PLN | 1.82% |
| 2013 | 32.97 Million PLN | 33.82% |
| 2012 | 24.64 Million PLN | -37.05% |
| 2011 | 39.14 Million PLN | 26.55% |
| 2010 | 30.93 Million PLN | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 13.9 Million PLN | -31.0% |
| 2024 Q2 | 15.19 Million PLN | 9.31% |
| 2023 Q4 | 20.14 Million PLN | 148.62% |
| 2023 Q3 | 8.1 Million PLN | -55.86% |
| 2023 Q2 | 18.35 Million PLN | 53.02% |
| 2023 FY | 58.6 Million PLN | 16.32% |
| 2023 Q1 | 11.99 Million PLN | -16.12% |
| 2022 Q4 | 14.3 Million PLN | 6.34% |
| 2022 Q3 | 13.44 Million PLN | -3.98% |
| 2022 Q2 | 14 Million PLN | 62.42% |
| 2022 Q1 | 8.62 Million PLN | -40.9% |
| 2022 FY | 50.38 Million PLN | 22.43% |
| 2021 Q1 | 5.55 Million PLN | -54.21% |
| 2021 Q2 | 14.46 Million PLN | 160.35% |
| 2021 Q3 | 6.54 Million PLN | -54.72% |
| 2021 FY | 41.15 Million PLN | 2.48% |
| 2021 Q4 | 14.59 Million PLN | 122.83% |
| 2020 Q4 | 12.12 Million PLN | 45.61% |
| 2020 FY | 40.15 Million PLN | 2.69% |
| 2020 Q1 | 10.41 Million PLN | -18.29% |
| 2020 Q2 | 9.28 Million PLN | -10.89% |
| 2020 Q3 | 8.33 Million PLN | -10.27% |
| 2019 FY | 39.1 Million PLN | 21.1% |
| 2019 Q1 | 9.81 Million PLN | 7.61% |
| 2019 Q2 | 8.55 Million PLN | -12.85% |
| 2019 Q3 | 7.99 Million PLN | -6.58% |
| 2019 Q4 | 12.74 Million PLN | 59.56% |
| 2018 Q4 | 9.12 Million PLN | 3.59% |
| 2018 Q3 | 8.8 Million PLN | 21.38% |
| 2018 Q2 | 7.25 Million PLN | 1.93% |
| 2018 Q1 | 7.11 Million PLN | -10.98% |
| 2018 FY | 32.29 Million PLN | 2.83% |
| 2017 Q3 | 8.83 Million PLN | 55.01% |
| 2017 FY | 31.4 Million PLN | -13.58% |
| 2017 Q4 | 7.99 Million PLN | -9.51% |
| 2017 Q2 | 5.69 Million PLN | -35.8% |
| 2017 Q1 | 8.87 Million PLN | 9.89% |
| 2016 Q3 | 9.19 Million PLN | -15.43% |
| 2016 Q4 | 8.07 Million PLN | -12.19% |
| 2016 FY | 36.33 Million PLN | -14.67% |
| 2016 Q1 | 8.18 Million PLN | -53.74% |
| 2016 Q2 | 10.87 Million PLN | 32.87% |
| 2015 Q2 | 12.32 Million PLN | 203.75% |
| 2015 Q3 | 8.51 Million PLN | -30.93% |
| 2015 FY | 42.58 Million PLN | 26.84% |
| 2015 Q4 | 17.69 Million PLN | 107.89% |
| 2015 Q1 | 4.05 Million PLN | -68.41% |
| 2014 Q3 | 6.71 Million PLN | -9.53% |
| 2014 FY | 33.57 Million PLN | 1.82% |
| 2014 Q1 | 7.68 Million PLN | -17.63% |
| 2014 Q2 | 7.42 Million PLN | -3.43% |
| 2014 Q4 | 12.84 Million PLN | 91.2% |
| 2013 Q4 | 9.33 Million PLN | 22.4% |
| 2013 Q2 | 7.62 Million PLN | -9.17% |
| 2013 Q3 | 7.62 Million PLN | 0.03% |
| 2013 Q1 | 8.39 Million PLN | 52.42% |
| 2013 FY | 32.97 Million PLN | 33.82% |
| 2012 Q4 | 5.5 Million PLN | 118.98% |
| 2012 FY | 24.64 Million PLN | -37.05% |
| 2012 Q2 | 7.33 Million PLN | -21.0% |
| 2012 Q3 | 2.51 Million PLN | -65.72% |
| 2012 Q1 | 9.28 Million PLN | 0.0% |
| 2011 FY | 39.14 Million PLN | 26.55% |
| 2010 FY | 30.93 Million PLN | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Bioceltix S.A. | - PLN | -Infinity% |
| BIOTON S.A. | 181.63 Million PLN | 67.734% |
| Captor Therapeutics Spolka Akcyjna | 13.2 Million PLN | -343.959% |
| Mabion S.A. | 151.67 Million PLN | 61.361% |
| Molecure S.A. | 100.00 PLN | -58606900.0% |
| NanoGroup S.A. | 2019.00 PLN | -2902673.65% |
| Pharmena S.A. | 9.83 Million PLN | -495.781% |
| Poltreg S.A. | 1.39 Million PLN | -4089.207% |
| Pure Biologics Spólka Akcyjna | 95 Thousand PLN | -61591.579% |
| Ryvu Therapeutics S.A. | 46.86 Million PLN | -25.068% |
| Urteste S.A. | - PLN | -Infinity% |